Triple Inhaler versus Dual Bronchodilator Therapy in COPD: Real-World Effectiveness on Mortality

Randomized trials of triple therapy including an inhaled corticosteroid (ICS) for chronic obstructive pulmonary disease (COPD) reported remarkable benefits on mortality compared with dual bronchodilators, likely resulting from ICS withdrawal at randomization. We compared triple therapy with dual bro...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Chronic obstructive pulmonary disease Ročník 19; číslo 1; s. 1 - 9
Hlavní autoři:	Suissa, Samy, Dell'Aniello, Sophie, Ernst, Pierre
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Taylor & Francis 01.12.2022 Taylor & Francis Group
Témata:	Administration, Inhalation Adrenal Cortex Hormones - therapeutic use Adrenergic beta-2 Receptor Agonists - therapeutic use Bronchodilator Agents - therapeutic use Drug Therapy, Combination exacerbations Humans inhaled coticosteroids long-acting bronchodilators Middle Aged Muscarinic Antagonists Nebulizers and Vaporizers New-user cohort design observational research pneumonia Pneumonia - etiology Pulmonary Disease, Chronic Obstructive real-world evidence New-user cohort design real-world evidence pneumonia exacerbations long-acting bronchodilators observational research inhaled coticosteroids
ISSN:	1541-2555, 1541-2563, 1541-2563
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Randomized trials of triple therapy including an inhaled corticosteroid (ICS) for chronic obstructive pulmonary disease (COPD) reported remarkable benefits on mortality compared with dual bronchodilators, likely resulting from ICS withdrawal at randomization. We compared triple therapy with dual bronchodilator combinations on major COPD outcomes in a real-world clinical practice setting. We identified a cohort of COPD patients, age 50 or older, treated during 2002-2018, from the United Kingdom's Clinical Practice Research Datalink. Patients initiating treatment with a long-acting muscarinic antagonist (LAMA), a long-acting beta 2 -agonist (LABA) and an ICS on the same day, were compared with patients initiating a LAMA and LABA, weighted by fine stratification of propensity scores. Subjects were followed-up one year for all-cause mortality, severe exacerbation and pneumonia. The cohort included 117,729 new-users of LAMA-LABA-ICS and 26,666 of LAMA-LABA. The adjusted hazard ratio (HR) of all-cause mortality with LAMA-LABA-ICS compared with LAMA-LABA was 1.17 (95% CI: 1.04-1.31) while for severe exacerbation and pneumonia it was 1.19 (1.08-1.32) and 1.29 (1.16-1.45) respectively. However, mortality was not elevated with triple therapy among patients with asthma diagnosis (HR 0.99; 95% CI: 0.74-1.34), with two or more prior exacerbations (HR 0.88; 95% CI: 0.70-1.11), and with FEV 1 percent predicted >30%. In a real-world setting of COPD treatment, triple therapy initiation was not more effective than dual bronchodilators at preventing all-cause mortality and severe COPD exacerbations. Triple therapy may be unsafe among patients without prior exacerbations, in whom ICS are not recommended, with no asthma diagnosis and with very severe airflow obstruction. Supplemental data for this article is available online at https://doi.org/10.1080/15412555.2021.1977789 .
AbstractList	Randomized trials of triple therapy including an inhaled corticosteroid (ICS) for chronic obstructive pulmonary disease (COPD) reported remarkable benefits on mortality compared with dual bronchodilators, likely resulting from ICS withdrawal at randomization. We compared triple therapy with dual bronchodilator combinations on major COPD outcomes in a real-world clinical practice setting. We identified a cohort of COPD patients, age 50 or older, treated during 2002-2018, from the United Kingdom's Clinical Practice Research Datalink. Patients initiating treatment with a long-acting muscarinic antagonist (LAMA), a long-acting beta -agonist (LABA) and an ICS on the same day, were compared with patients initiating a LAMA and LABA, weighted by fine stratification of propensity scores. Subjects were followed-up one year for all-cause mortality, severe exacerbation and pneumonia. The cohort included 117,729 new-users of LAMA-LABA-ICS and 26,666 of LAMA-LABA. The adjusted hazard ratio (HR) of all-cause mortality with LAMA-LABA-ICS compared with LAMA-LABA was 1.17 (95% CI: 1.04-1.31) while for severe exacerbation and pneumonia it was 1.19 (1.08-1.32) and 1.29 (1.16-1.45) respectively. However, mortality was not elevated with triple therapy among patients with asthma diagnosis (HR 0.99; 95% CI: 0.74-1.34), with two or more prior exacerbations (HR 0.88; 95% CI: 0.70-1.11), and with FEV percent predicted >30%. In a real-world setting of COPD treatment, triple therapy initiation was not more effective than dual bronchodilators at preventing all-cause mortality and severe COPD exacerbations. Triple therapy may be unsafe among patients without prior exacerbations, in whom ICS are not recommended, with no asthma diagnosis and with very severe airflow obstruction.Supplemental data for this article is available online at https://doi.org/10.1080/15412555.2021.1977789 . Randomized trials of triple therapy including an inhaled corticosteroid (ICS) for chronic obstructive pulmonary disease (COPD) reported remarkable benefits on mortality compared with dual bronchodilators, likely resulting from ICS withdrawal at randomization. We compared triple therapy with dual bronchodilator combinations on major COPD outcomes in a real-world clinical practice setting. We identified a cohort of COPD patients, age 50 or older, treated during 2002-2018, from the United Kingdom's Clinical Practice Research Datalink. Patients initiating treatment with a long-acting muscarinic antagonist (LAMA), a long-acting beta 2 -agonist (LABA) and an ICS on the same day, were compared with patients initiating a LAMA and LABA, weighted by fine stratification of propensity scores. Subjects were followed-up one year for all-cause mortality, severe exacerbation and pneumonia. The cohort included 117,729 new-users of LAMA-LABA-ICS and 26,666 of LAMA-LABA. The adjusted hazard ratio (HR) of all-cause mortality with LAMA-LABA-ICS compared with LAMA-LABA was 1.17 (95% CI: 1.04-1.31) while for severe exacerbation and pneumonia it was 1.19 (1.08-1.32) and 1.29 (1.16-1.45) respectively. However, mortality was not elevated with triple therapy among patients with asthma diagnosis (HR 0.99; 95% CI: 0.74-1.34), with two or more prior exacerbations (HR 0.88; 95% CI: 0.70-1.11), and with FEV 1 percent predicted >30%. In a real-world setting of COPD treatment, triple therapy initiation was not more effective than dual bronchodilators at preventing all-cause mortality and severe COPD exacerbations. Triple therapy may be unsafe among patients without prior exacerbations, in whom ICS are not recommended, with no asthma diagnosis and with very severe airflow obstruction. Supplemental data for this article is available online at https://doi.org/10.1080/15412555.2021.1977789 . Randomized trials of triple therapy including an inhaled corticosteroid (ICS) for chronic obstructive pulmonary disease (COPD) reported remarkable benefits on mortality compared with dual bronchodilators, likely resulting from ICS withdrawal at randomization. We compared triple therapy with dual bronchodilator combinations on major COPD outcomes in a real-world clinical practice setting. We identified a cohort of COPD patients, age 50 or older, treated during 2002-2018, from the United Kingdom’s Clinical Practice Research Datalink. Patients initiating treatment with a long-acting muscarinic antagonist (LAMA), a long-acting beta2-agonist (LABA) and an ICS on the same day, were compared with patients initiating a LAMA and LABA, weighted by fine stratification of propensity scores. Subjects were followed-up one year for all-cause mortality, severe exacerbation and pneumonia. The cohort included 117,729 new-users of LAMA-LABA-ICS and 26,666 of LAMA-LABA. The adjusted hazard ratio (HR) of all-cause mortality with LAMA-LABA-ICS compared with LAMA-LABA was 1.17 (95% CI: 1.04-1.31) while for severe exacerbation and pneumonia it was 1.19 (1.08-1.32) and 1.29 (1.16-1.45) respectively. However, mortality was not elevated with triple therapy among patients with asthma diagnosis (HR 0.99; 95% CI: 0.74-1.34), with two or more prior exacerbations (HR 0.88; 95% CI: 0.70-1.11), and with FEV1 percent predicted >30%. In a real-world setting of COPD treatment, triple therapy initiation was not more effective than dual bronchodilators at preventing all-cause mortality and severe COPD exacerbations. Triple therapy may be unsafe among patients without prior exacerbations, in whom ICS are not recommended, with no asthma diagnosis and with very severe airflow obstruction.Supplemental data for this article is available online at https://doi.org/10.1080/15412555.2021.1977789 . Randomized trials of triple therapy including an inhaled corticosteroid (ICS) for chronic obstructive pulmonary disease (COPD) reported remarkable benefits on mortality compared with dual bronchodilators, likely resulting from ICS withdrawal at randomization. We compared triple therapy with dual bronchodilator combinations on major COPD outcomes in a real-world clinical practice setting. We identified a cohort of COPD patients, age 50 or older, treated during 2002-2018, from the United Kingdom's Clinical Practice Research Datalink. Patients initiating treatment with a long-acting muscarinic antagonist (LAMA), a long-acting beta2-agonist (LABA) and an ICS on the same day, were compared with patients initiating a LAMA and LABA, weighted by fine stratification of propensity scores. Subjects were followed-up one year for all-cause mortality, severe exacerbation and pneumonia. The cohort included 117,729 new-users of LAMA-LABA-ICS and 26,666 of LAMA-LABA. The adjusted hazard ratio (HR) of all-cause mortality with LAMA-LABA-ICS compared with LAMA-LABA was 1.17 (95% CI: 1.04-1.31) while for severe exacerbation and pneumonia it was 1.19 (1.08-1.32) and 1.29 (1.16-1.45) respectively. However, mortality was not elevated with triple therapy among patients with asthma diagnosis (HR 0.99; 95% CI: 0.74-1.34), with two or more prior exacerbations (HR 0.88; 95% CI: 0.70-1.11), and with FEV1 percent predicted >30%. In a real-world setting of COPD treatment, triple therapy initiation was not more effective than dual bronchodilators at preventing all-cause mortality and severe COPD exacerbations. Triple therapy may be unsafe among patients without prior exacerbations, in whom ICS are not recommended, with no asthma diagnosis and with very severe airflow obstruction.Supplemental data for this article is available online at https://doi.org/10.1080/15412555.2021.1977789 .Randomized trials of triple therapy including an inhaled corticosteroid (ICS) for chronic obstructive pulmonary disease (COPD) reported remarkable benefits on mortality compared with dual bronchodilators, likely resulting from ICS withdrawal at randomization. We compared triple therapy with dual bronchodilator combinations on major COPD outcomes in a real-world clinical practice setting. We identified a cohort of COPD patients, age 50 or older, treated during 2002-2018, from the United Kingdom's Clinical Practice Research Datalink. Patients initiating treatment with a long-acting muscarinic antagonist (LAMA), a long-acting beta2-agonist (LABA) and an ICS on the same day, were compared with patients initiating a LAMA and LABA, weighted by fine stratification of propensity scores. Subjects were followed-up one year for all-cause mortality, severe exacerbation and pneumonia. The cohort included 117,729 new-users of LAMA-LABA-ICS and 26,666 of LAMA-LABA. The adjusted hazard ratio (HR) of all-cause mortality with LAMA-LABA-ICS compared with LAMA-LABA was 1.17 (95% CI: 1.04-1.31) while for severe exacerbation and pneumonia it was 1.19 (1.08-1.32) and 1.29 (1.16-1.45) respectively. However, mortality was not elevated with triple therapy among patients with asthma diagnosis (HR 0.99; 95% CI: 0.74-1.34), with two or more prior exacerbations (HR 0.88; 95% CI: 0.70-1.11), and with FEV1 percent predicted >30%. In a real-world setting of COPD treatment, triple therapy initiation was not more effective than dual bronchodilators at preventing all-cause mortality and severe COPD exacerbations. Triple therapy may be unsafe among patients without prior exacerbations, in whom ICS are not recommended, with no asthma diagnosis and with very severe airflow obstruction.Supplemental data for this article is available online at https://doi.org/10.1080/15412555.2021.1977789 .
Author	Ernst, Pierre Suissa, Samy Dell'Aniello, Sophie
Author_xml	– sequence: 1 givenname: Samy orcidid: 0000-0002-1281-5296 surname: Suissa fullname: Suissa, Samy organization: Department of Epidemiology and Biostatistics, McGill University – sequence: 2 givenname: Sophie surname: Dell'Aniello fullname: Dell'Aniello, Sophie organization: Department of Epidemiology and Biostatistics, McGill University – sequence: 3 givenname: Pierre orcidid: 0000-0001-9983-3608 surname: Ernst fullname: Ernst, Pierre organization: Department of Epidemiology and Biostatistics, McGill University
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/34544314$$D View this record in MEDLINE/PubMed
BookMark	eNqFkUtvEzEQx1eoiD7gI4B85LLB9vq1cKGkBSIVFaEgjmZie4krxw62tyjfnoQkPXCA04xG_4c0v_PmJKbomuY5wROCFX5FOCOUcz6hmJIJ6aWUqn_UnO3uLeWiO3nYOT9tzku5w5hy1vEnzWnHOGMdYWfN93n26-DQLC4huIzuXS5jQVcjBPQup2iWyfoANWU0X7oM6w3yEU1vP1-9Rl8chPZbysGi62Fwpvp7F10pKEX0KeUKwdfN0-bxAKG4Z4d50Xx9fz2ffmxvbj_Mppc3reGM11YJUJwwxWUviMBMYmll7yxgA7ZndsEVk6CkHQR0hA_KcKksoULxQdAFdBfNbJ9rE9zpdfYryBudwOs_h5R_aMjVm-A0ENlThSX0YJhcdEAxI9b0wogeL5jZZr3cZ61z-jm6UvXKF-NCgOjSWDTlkmMhOkG30hcH6bhYOftQfPzwVvBmLzA5lZLdoI2vUH2KNYMPmmC946mPPPWOpz7w3Lr5X-5jwf98b_c-H4eUV_BrR0lX2ISUhwzR-KK7f0f8BqvqtIs
CitedBy_id	crossref_primary_10_1016_j_pulmoe_2022_11_001 crossref_primary_10_2147_COPD_S375190 crossref_primary_10_3390_jcm11226623 crossref_primary_10_2147_COPD_S424128 crossref_primary_10_1186_s12931_025_03234_5 crossref_primary_10_1186_s13020_025_01117_x crossref_primary_10_1590_1806_9282_20230721 crossref_primary_10_3390_jcm13206199 crossref_primary_10_1016_j_annepidem_2023_12_003 crossref_primary_10_2147_COPD_S413754 crossref_primary_10_1080_17512433_2022_2134113 crossref_primary_10_1016_j_arbres_2025_02_004 crossref_primary_10_1186_s12931_024_02918_8 crossref_primary_10_1177_17534666241292242 crossref_primary_10_1038_s41533_023_00347_6 crossref_primary_10_1080_15412555_2021_1998410 crossref_primary_10_3390_biom13020213 crossref_primary_10_1080_00325481_2023_2284650 crossref_primary_10_1164_rccm_202205_1000PP crossref_primary_10_1080_17512433_2024_2408272 crossref_primary_10_2147_COPD_S404039 crossref_primary_10_1080_15412555_2022_2035705
Cites_doi	10.1016/j.chest.2019.11.007 10.1093/aje/kwr364 10.1002/pds.3207 10.1183/13993003.00214-2017 10.1164/rccm.202003-0622ED 10.1136/bmj.l5657 10.1183/09031936.00080312 10.1164/rccm.202012-4300ED 10.1002/pds.4107 10.1002/pds.3334 10.1172/JCI109789 10.1164/rccm.202006-2618OC 10.1056/NEJMoa063070 10.2147/CLEP.S117867 10.1016/S2213-2600(17)30217-5 10.1016/j.chest.2019.03.005 10.1056/NEJMra1614394 10.1016/S0140-6736(16)30069-1 10.1183/13993003.00671-2017 10.1164/rccm.201911-2207OC 10.1056/NEJMe1716802 10.1183/13993003.01848-2018 10.1183/13993003.00361-2017 10.1016/S2213-2600(21)00238-1 10.1111/j.1365-2125.2009.03537.x 10.1016/S2213-2600(18)30368-0 10.1080/15412555.2021.1877649 10.1093/ije/dyz034 10.1056/NEJMoa1608033 10.1056/NEJMc1807380 10.1056/NEJMsb1609216 10.1136/bmjopen-2014-005540 10.1093/ije/dyv098 10.1007/s41030-020-00132-7 10.1002/pds.4448
ContentType	Journal Article
Copyright	2021 The Author(s). Published with license by Taylor & Francis Group, LLC. 2021
Copyright_xml	– notice: 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. 2021
DBID	0YH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 DOA
DOI	10.1080/15412555.2021.1977789
DatabaseName	Taylor & Francis Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 0YH name: Taylor & Francis Open Access url: https://www.tandfonline.com sourceTypes: Publisher – sequence: 4 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1541-2563
EndPage	9
ExternalDocumentID	oai_doaj_org_article_a1792807a9ac47b3a2041dc96c690b4c 34544314 10_1080_15412555_2021_1977789 1977789
Genre	Research Article Research Support, Non-U.S. Gov't Journal Article
GrantInformation_xml	– fundername: CIHR
GroupedDBID	--- 00X 03L 0YH 29B 4.4 5GY AALUX ABDBF ABEIZ ABLKL ABUPF ACGEJ ACGFS ACUHS ADCVX ADRBQ ADXPE AECIN AEOZL AGYJP AIJEM ALMA_UNASSIGNED_HOLDINGS ALQZU AQTUD BABNJ BLEHA BOHLJ CCCUG CS3 DKSSO EBD EBS EMOBN ESX F5P GROUPED_DOAJ H13 HZ~ KRBQP KSSTO KWAYT KYCEM LJTGL M4Z O9- OK1 SV3 TDBHL TFDNU TFL TFW TUS V1S ~1N AAYXX CITATION 53G 5VS AALIY ACENM ACKZS ADFZZ AFFVI AWYRJ CAG CGR COF CUY CVF CZDIS DRXRE DWTOO ECM EIF EJD M44 NPM S70 7X8
ID	FETCH-LOGICAL-c545t-86a8514857961604707d79eda0cad94db5847a87df6a315f8c578d12685f62ba3
IEDL.DBID	DOA
ISICitedReferencesCount	25
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000697631100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1541-2555 1541-2563
IngestDate	Fri Oct 03 12:44:51 EDT 2025 Fri Jul 11 12:22:06 EDT 2025 Thu Jan 02 22:54:50 EST 2025 Tue Nov 18 22:37:28 EST 2025 Sat Nov 29 07:37:54 EST 2025 Mon Oct 20 23:45:53 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	New-user cohort design real-world evidence pneumonia exacerbations long-acting bronchodilators observational research inhaled coticosteroids
Language	English
License	open-access: http://creativecommons.org/licenses/by-nc/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c545t-86a8514857961604707d79eda0cad94db5847a87df6a315f8c578d12685f62ba3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ORCID	0000-0001-9983-3608 0000-0002-1281-5296
OpenAccessLink	https://doaj.org/article/a1792807a9ac47b3a2041dc96c690b4c
PMID	34544314
PQID	2575066362
PQPubID	23479
PageCount	9
ParticipantIDs	doaj_primary_oai_doaj_org_article_a1792807a9ac47b3a2041dc96c690b4c informaworld_taylorfrancis_310_1080_15412555_2021_1977789 proquest_miscellaneous_2575066362 pubmed_primary_34544314 crossref_citationtrail_10_1080_15412555_2021_1977789 crossref_primary_10_1080_15412555_2021_1977789
PublicationCentury	2000
PublicationDate	2022-12-00
PublicationDateYYYYMMDD	2022-12-01
PublicationDate_xml	– month: 12 year: 2022 text: 2022-12-00
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	Chronic obstructive pulmonary disease
PublicationTitleAlternate	COPD
PublicationYear	2022
Publisher	Taylor & Francis Taylor & Francis Group
Publisher_xml	– name: Taylor & Francis – name: Taylor & Francis Group
References	e_1_3_4_4_1 e_1_3_4_3_1 e_1_3_4_2_1 e_1_3_4_9_1 e_1_3_4_8_1 e_1_3_4_7_1 e_1_3_4_20_1 e_1_3_4_6_1 e_1_3_4_5_1 e_1_3_4_23_1 e_1_3_4_24_1 e_1_3_4_21_1 e_1_3_4_22_1 e_1_3_4_27_1 e_1_3_4_28_1 e_1_3_4_25_1 e_1_3_4_26_1 e_1_3_4_29_1 e_1_3_4_31_1 e_1_3_4_30_1 e_1_3_4_12_1 e_1_3_4_35_1 e_1_3_4_13_1 e_1_3_4_34_1 e_1_3_4_10_1 e_1_3_4_33_1 e_1_3_4_11_1 e_1_3_4_32_1 e_1_3_4_16_1 e_1_3_4_17_1 e_1_3_4_14_1 e_1_3_4_37_1 e_1_3_4_15_1 e_1_3_4_36_1 e_1_3_4_18_1 e_1_3_4_19_1 35050797 - COPD. 2022;19(1):57-60
References_xml	– ident: e_1_3_4_22_1 doi: 10.1016/j.chest.2019.11.007 – ident: e_1_3_4_28_1 doi: 10.1093/aje/kwr364 – ident: e_1_3_4_26_1 doi: 10.1002/pds.3207 – ident: e_1_3_4_2_1 doi: 10.1183/13993003.00214-2017 – ident: e_1_3_4_7_1 doi: 10.1164/rccm.202003-0622ED – ident: e_1_3_4_25_1 doi: 10.1136/bmj.l5657 – ident: e_1_3_4_30_1 doi: 10.1183/09031936.00080312 – ident: e_1_3_4_8_1 doi: 10.1164/rccm.202012-4300ED – ident: e_1_3_4_24_1 doi: 10.1002/pds.4107 – ident: e_1_3_4_23_1 doi: 10.1002/pds.3334 – ident: e_1_3_4_36_1 doi: 10.1172/JCI109789 – ident: e_1_3_4_6_1 doi: 10.1164/rccm.202006-2618OC – ident: e_1_3_4_33_1 doi: 10.1056/NEJMoa063070 – ident: e_1_3_4_20_1 doi: 10.2147/CLEP.S117867 – ident: e_1_3_4_32_1 – ident: e_1_3_4_37_1 doi: 10.1016/S2213-2600(17)30217-5 – ident: e_1_3_4_27_1 doi: 10.1016/j.chest.2019.03.005 – ident: e_1_3_4_14_1 doi: 10.1056/NEJMra1614394 – ident: e_1_3_4_34_1 doi: 10.1016/S0140-6736(16)30069-1 – ident: e_1_3_4_4_1 doi: 10.1183/13993003.00671-2017 – ident: e_1_3_4_5_1 doi: 10.1164/rccm.201911-2207OC – ident: e_1_3_4_10_1 doi: 10.1056/NEJMe1716802 – ident: e_1_3_4_11_1 doi: 10.1183/13993003.01848-2018 – ident: e_1_3_4_31_1 doi: 10.1183/13993003.00361-2017 – ident: e_1_3_4_9_1 doi: 10.1016/S2213-2600(21)00238-1 – ident: e_1_3_4_17_1 doi: 10.1111/j.1365-2125.2009.03537.x – ident: e_1_3_4_21_1 doi: 10.1016/S2213-2600(18)30368-0 – ident: e_1_3_4_15_1 doi: 10.1080/15412555.2021.1877649 – ident: e_1_3_4_16_1 doi: 10.1093/ije/dyz034 – ident: e_1_3_4_35_1 doi: 10.1056/NEJMoa1608033 – ident: e_1_3_4_12_1 doi: 10.1056/NEJMc1807380 – ident: e_1_3_4_13_1 doi: 10.1056/NEJMsb1609216 – ident: e_1_3_4_19_1 doi: 10.1136/bmjopen-2014-005540 – ident: e_1_3_4_18_1 doi: 10.1093/ije/dyv098 – ident: e_1_3_4_3_1 doi: 10.1007/s41030-020-00132-7 – ident: e_1_3_4_29_1 doi: 10.1002/pds.4448 – reference: 35050797 - COPD. 2022;19(1):57-60
SSID	ssj0025435
Score	2.449013
Snippet	Randomized trials of triple therapy including an inhaled corticosteroid (ICS) for chronic obstructive pulmonary disease (COPD) reported remarkable benefits on...
SourceID	doaj proquest pubmed crossref informaworld
SourceType	Open Website Aggregation Database Index Database Enrichment Source Publisher
StartPage	1
SubjectTerms	Administration, Inhalation Adrenal Cortex Hormones - therapeutic use Adrenergic beta-2 Receptor Agonists - therapeutic use Bronchodilator Agents - therapeutic use Drug Therapy, Combination exacerbations Humans inhaled coticosteroids long-acting bronchodilators Middle Aged Muscarinic Antagonists Nebulizers and Vaporizers New-user cohort design observational research pneumonia Pneumonia - etiology Pulmonary Disease, Chronic Obstructive real-world evidence
SummonAdditionalLinks	– databaseName: Taylor & Francis Open Access dbid: 0YH link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB5BQYgL5dWyFCojcU2JHcdOeqMtVZHaUqEFlZNx7KRdqcqiZLe_vzOOswKkqgfIMfLkYc_jG3v8GeC9trxxNaUlFRq5xCsprVOJrrx3hRNZHngKvh_r09Pi_Lw8i9WEfSyrpBy6GYgigq8m47ZVP1bEfcCoj2E5zzG7E3yHI4LRRXkfHghMTaiqK_1xtMq5chnO2CSRhGTGTTy3PeaP8BRY_P_iML0diYaIdLj-H_7lKTyJcJR9HPTnGdyr2-fw6CQuuL-An9OOZuLZ5_YSI0nHqIhj2bODJQphBt-i8_SzK0rc2XTgJ2Czlu1_OTvYZV8RgyahWIcNHMnRsbJ5y04C6scM4CV8O_w03T9K4qEMiUOwtUgKZRGkyYL2sHKVSp1qr8va29RZX0pf0bqrLbRvlM143hQOfYLnQhV5o0Rlsw1Ya-dt_QpYhmAI0ZcXRKGfOmya5bJBhKIctmvkBOQ4FsZFxnI6OOPK8EhsOvaeod4zsfcmsLMS-zVQdtwlsEcDvWpMjNvhxry7MNGAjUXPRcxBFlVZ6iqzIpXcu1I5VaaVdBMof1cTswgTLs1wOorJ7viAd6NOGbRuWrKxbT1f9gYdak6gUIkJbA7KtvrMTBJ3IZev_-HNW_BY0H6OUJ_zBtYW3bJ-Cw_d9WLWd9vBlG4A_kIVWw priority: 102 providerName: Taylor & Francis
Title	Triple Inhaler versus Dual Bronchodilator Therapy in COPD: Real-World Effectiveness on Mortality
URI	https://www.tandfonline.com/doi/abs/10.1080/15412555.2021.1977789 https://www.ncbi.nlm.nih.gov/pubmed/34544314 https://www.proquest.com/docview/2575066362 https://doaj.org/article/a1792807a9ac47b3a2041dc96c690b4c
Volume	19
WOSCitedRecordID	wos000697631100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1541-2563 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025435 issn: 1541-2555 databaseCode: DOA dateStart: 20220101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVAWR databaseName: Taylor & Francis Journals Complete customDbUrl: eissn: 1541-2563 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025435 issn: 1541-2555 databaseCode: TFW dateStart: 20040101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis – providerCode: PRVAWR databaseName: Taylor & Francis Open Access customDbUrl: eissn: 1541-2563 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0025435 issn: 1541-2555 databaseCode: 0YH dateStart: 20221201 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB7SEEovpU1fmxcq9OrEsmVJzq1JuqSQpCFs2u1JlSWbLgRv2Ud-f2ZkeVkKZS_1QQchGTGaGX2jxzcAn5TljaspLKnQyAV-SWmdTFTlvdMuy4vAU_D9St3c6PG4vF1L9UV3wjp64E5wJxY1hhhbLP5CqCq3WSq4d6V0GNdVwpH3RdTTB1Mx1CpESK2J-IAnCJqL_u2OTk-ojqowNsz4MUf8oyjH-9qqFMj7_6Iu_TcADQvR8BW8jAiSfe5G_hq26nYXnl_HM_I38Gs0o81z9rX9jc5_xujexXLOLpbYCYPuFv2dnzxQrM1GHaUAm7Ts_NvtxSm7Q9iYhPs1rKM1jr6QTVt2HYA6gva3cD_8Mjq_TGIehcQhPlokWlrEVULTs1MuU6FS5VVZe5s660vhKzoqtVr5RtqcF412aMaeZ1IXjcwqm7-D7Xba1h-A5YhfEDD5jFjvU4dN80I0CCqkw3aNGIDo5WhcJBmnXBcPhkcu0l78hsRvovgHcLzq9qdj2djU4YwmadWYSLJDBaqOiapjNqnOAMr1KTaLsEfSdAlNTL5hAB97fTBokHTKYtt6upwb9IEF4TiZDeB9pyirYeaC6Aa52Psfw9-HFxm9xQh3aw5gezFb1oew4x4Xk_nsCJ6lPy-xVGN9FGwDy9HwxxOS5weE
linkProvider	Directory of Open Access Journals
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB5BQcClvAosTyNxTRsnfiTcSsuqFbsLQgF6cx07aVeqsii7y-9nxklWBanqAXKMPHnY8_jGHn8GeKctr11FaUmJRi7winLrVKRL713mklQGnoLvEz2bZScn-eW9MFRWSTl03RFFBF9Nxk2T0UNJ3B6GfYzLUmJ6l_BdjhBGZ_lNuCUx1lJZXzH-sUm6pAiHbJJIRDLDLp6rHvNHfAo0_n-RmF4NRUNIGt__Hz_zALZ7QMr2Ow16CDeq5hHcmfZL7o_htGhpLp4dN-cYS1pGZRzrJTtcoxDm8A26Tz-_oNSdFR1DAZs37ODzl8P37Cui0CiU67COJbl3rWzRsGnA_ZgD7MC38cfi4Cjqj2WIHMKtVZQpizBNZLSLlatY6Fh7nVfexs76XPiSVl5tpn2tbMplnTn0Cp4nKpO1SkqbPoGtZtFUz4ClCIcQf_mESPRjh01TKWrEKMphu1qMQAyDYVzPWU5HZ1wY3lObDr1nqPdM33sj2N2I_exIO64T-EAjvWlMnNvhxqI9M70JG4u-i7iDLCqz0GVqk1hw73LlVB6Xwo0gv6wnZhWmXOrufBSTXvMBbwelMmjftGhjm2qxXhp0qZJgoUpG8LTTts1npoLYC7l4_g9vfgN3j4rpxEyOZ59ewL2EdneEap2XsLVq19UruO1-rebL9nWwq98KVBmF
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB5BQRUX3tDlaSSuKXHi2Ak36LKiol1WaIHeXMeO6UpVtsru8vuZcZwVIFU9QI6RJw97Ht_Y488Ar5Xh3jaUltRo5AKvpDJWJqp2zpY2y4vAU_DtSE2n5clJNYvVhKtYVkk5tO-JIoKvJuO-cH6oiHuDUR_DclFgdpfxfY4IRpXVdbgRyLFQpeeT79ucqxDhjE0SSUhm2MRz2WP-CE-Bxf8vDtPLkWiISJM7_-Ff7sLtCEfZu15_7sG1pr0Pu8dxwf0BnM47molnh-0ZRpKOURHHZsXGGxTCDL5F5-kW55S4s3nPT8AWLTv4PBu_ZV8QgyahWIf1HMnRsbJly44D6scM4CF8nXyYH3xM4qEMiUWwtU5KaRCkiZL2sHKZCpUqp6rGmdQaVwlX07qrKZXz0uS88KVFn-B4JsvCy6w2-SPYaZdtswcsRzCE6MtlRKGfWmyaF8IjQpEW23kxAjGMhbaRsZwOzjjXPBKbDr2nqfd07L0R7G_FLnrKjqsE3tNAbxsT43a4sex-6GjA2qDnIuYgg6osVJ2bLBXc2UpaWaW1sCOoflcTvQ4TLr4_HUXnV3zAq0GnNFo3LdmYtlluVhodakGgUGYjeNwr2_Yzc0HchVw8-Yc3v4Td2Xiijw6nn57CrYy2doRSnWews-42zXO4aX-uF6vuRbCqX2UuGCk
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Triple+Inhaler+versus+Dual+Bronchodilator+Therapy+in+COPD%3A+Real-World+Effectiveness+on+Mortality&rft.jtitle=Chronic+obstructive+pulmonary+disease&rft.au=Suissa%2C+Samy&rft.au=Dell%27Aniello%2C+Sophie&rft.au=Ernst%2C+Pierre&rft.date=2022-12-01&rft.eissn=1541-2563&rft.volume=19&rft.issue=1&rft.spage=1&rft_id=info:doi/10.1080%2F15412555.2021.1977789&rft_id=info%3Apmid%2F34544314&rft.externalDocID=34544314
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1541-2555&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1541-2555&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1541-2555&client=summon